AJCP / Meeting AbstrActs cardiovascular diseases. This primary effusion lymphoma is unique in several aspects including the occurrence in a nonimmune-suppressed patient, negative CD138 expression, and multiple confounding factors that may have contributed to the delay of diagnosis.
Introduction: Acute erythroid leukemia (AEL) is rare, accounting for <5% of acute myeloid leukemias (AMLs). The 2016 World Health Organization classification of myeloid neoplasms merged erythroleukemia with myelodysplastic syndrome (MDS) and retained the pure erythroid leukemia (PEL) type of AEL. PEL is defined as >80% immature erythroid precursors with ≥30% proerythroblasts. It commonly has a very complex karyotype and an extremely aggressive clinical course. PEL has recently been approved in metastatic prostate cancer with DNA-repair defects. Rare cases of, MDS/AML have been reported following treatment with olaparib. Here we reported a unique case of therapy-related PEL following olaparib treatment. Clinical History: A 69-year-old man had prostatic carcinoma, and was treated with androgen deprivation and radiation therapy. Two years later, he received multiple-agent chemotherapy for recurrent prostatic carcinoma, including olaparib (1.5 years), docetaxel, and Taxotere (three cycle). One year later, he developed sudden onset of pancytopenia, fever, elevated LDH, and transaminitis. His bone marrow biopsy was diagnosed as PEL, with >80% of early erythroid precursors and significant hemophagocytic lymphohistiocytosis. Cytogenetic studies showed a complex karyotype. The patient deceased within one week of admission due to multiorgan failure. Conclusions: MDS and AML are rare adverse events after olaparib regimen. However, all the patients reported had been heavily pretreated with other cytotoxic agents, and thus the determinant is difficult to decide. The interesting points in this case are as follows: (1) the patient is mainly treated with olaparib for 1.5 years before development of PEL; (2) to the best of our knowledge, this is the first report of PEL associated with olaparib therapy.
B-Lymphoblastic Leukemia With Aberrant T-Cell Antigen (CD5) Expression: A Rare Entity
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The immunophenotypic expression of the leukemic cells in B lymphoblastic leukemia can sometimes be asynchronous and aberrant. The expression of T-cell antigens in B lymphoblastic leukemia may sometimes complicate the lineage assignment in leukemia and raises concern for ambiguous lineage acute leukemia. However, per World Health Organization criteria, T-cell lineage assignment requires CD3 expression, and in the absence of CD3, the other T-cell antigens (eg, CD2, CD5, and CD7) are generally considered as aberrancies. Here, we highlight a rare case of a 14-year-old boy presenting with fatigue, intermittent fevers, night sweats, and leukocytosis of 130 k/mm 3 with circulating blasts. Follow-up bone marrow aspirate smears showed sheets of blasts (95%; which were positive for PAX5 and TdT by immunostains, and flow cytometry profile showed abnormal B lymphoblasts with aberrant expression of CD5. Expression of CD5 in B lymphoblastic leukemia is extremely rare, and its significance remains to be seen. However, the known reported cases have suggested it to be a poor prognosticator which may be a useful marker for identifying the future patients who are at increased risk for relapse and for harboring poor cytogenetic abnormalities. Therapy included dasatinib, cytarabine, and idarubicin. Complete morphologic remission was noted on day 63 with persistence of t(9;22) by cytogenetics. Case 2: The patient is a 62-year-old woman who presented with fatigue, weight loss, and leukocytosis. Bone marrow revealed blast forms (25%) and flow cytometry
